IBTA:NYSEIbotta, Inc. Analysis
Data as of 2026-05-19 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Ibotta, Inc. trades around $32, comfortably above its recent support of $28.5 but still below the 20‑day SMA of $34.6, indicating a near‑term price cushion yet lingering upside potential. Technicals show a bullish trend direction but a bearish MACD divergence and a neutral RSI near 44, suggesting momentum is waning. Volume is increasing, which supports the recent price gains, while the 30‑day volatility of roughly 46% signals a highly erratic price environment. Fundamentally, the company posted a modest revenue decline of 2.5% and negative operating margins, yet cash flow remains positive with $105.8 M operating cash and $63.7 M free cash, and the balance sheet is strong with $164.6 M cash versus $25.3 M debt. Forward earnings estimates are positive ($1.78 EPS) and the DCF fair value of $41.5 implies a modest upside of about 3½%, while the forward P/E of 18 is well below the industry average of 38, positioning the stock as relatively cheap. Recent news highlights a strategic partnership extension with the Denver Nuggets and a buyback program framed as a bullish signal, adding a layer of shareholder‑friendly activity. Overall, the stock sits at a crossroads where technical softness meets valuation comfort and solid liquidity, making it a candidate for cautious accumulation rather than aggressive speculation.
Market Outlook
Short Term
< 1 yearKey Factors
- Bearish MACD histogram indicating weakening momentum
- Price still above key support level
- High short‑term volatility
Medium Term
1–3 yearsKey Factors
- DCF fair value above current price suggesting upside
- Positive forward EPS and forward P/E well below industry average
- Increasing volume and cash‑rich balance sheet
Long Term
> 3 yearsKey Factors
- Strategic partnership extensions and buyback program
- Ongoing margin pressure and revenue contraction
- Potential for operational turnaround as cash flow remains solid
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.